Literature DB >> 30060174

Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study.

Michele Massimo Gulizia1,2, Roberto Cemin3, Furio Colivicchi4, Leonardo De Luca5, Andrea Di Lenarda6, Giuseppe Boriani7, Giuseppe Di Pasquale8, Federico Nardi9, Marino Scherillo10, Donata Lucci2, Gianna Fabbri2, Aldo Pietro Maggioni2.   

Abstract

AIMS: To assess the number of admissions to the emergency room (ER) of patients with atrial fibrillation (AF) or atrial flutter (af) and their subsequent management. To evaluate the clinical profile and the use of antithrombotics and antiarrhythmic therapy in patients with AF admitted to cardiology wards. METHODS AND
RESULTS: BLITZ-AF is a multicentre, observational study conducted in 154 centres on patients with AF/af. In each centre, data were collected, retrospectively for 4 weeks in ER and prospectively for 12 weeks in cardiology wards. In ER, there were 6275 admissions. Atrial fibrillation was the main diagnosis in 52.9% of the cases, af in 5.9%. Atrial fibrillation represented 1.0% of all ER admissions and 1.7% of all hospital admissions. A cardioversion has been performed in nearly 25% of the cases. Out of 4126 patients, 52.2% were admitted in cardiology ward; mean age was 74 ± 11 years, 41% were females. Patients with non-valvular AF were 3848 (93.3%); CHA2DS2-VASc score was ≥2 in 87.4%. Cardioversion was attempted in 38.8% of the patients. In-hospital mortality was 1.2%. At discharge, 42.6% of the patients were treated with vitamin K antagonists, 39.5% with direct oral anticoagulants, 13.6% with other antithrombotic drugs, and 4.2% did not take any antithrombotic agent. Rate control strategy was pursued in 47.2%, rhythm control in 44.0%, 45.6% were discharged in sinus rhythm.
CONCLUSION: Atrial fibrillation still represents a significant burden on health care system. Oral anticoagulant use increased over time even if compliance with guidelines, with respect to prevention of the risk of stroke, remains suboptimal.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30060174     DOI: 10.1093/europace/euy166

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Atrial fibrillation pattern and factors affecting the progression to permanent atrial fibrillation.

Authors:  Vincenzo Livio Malavasi; Elisa Fantecchi; Virginia Tordoni; Laura Melara; Andrea Barbieri; Marco Vitolo; Gregory Y H Lip; Giuseppe Boriani
Journal:  Intern Emerg Med       Date:  2020-11-07       Impact factor: 3.397

2.  From Bench to Bedside-Implementing the New ABC Approach for Atrial Fibrillation in an Emergency Department Setting.

Authors:  Sophie Gupta; Martin Lutnik; Jan Niederdöckl; Sebastian Schnaubelt
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 4.614

3.  Impact of a Multidisciplinary Treatment Pathway for Atrial Fibrillation in the Emergency Department on Hospital Admissions and Length of Stay: Results of a Multi-Center Study.

Authors:  Leon M Ptaszek; Christopher W Baugh; Steven A Lubitz; Jeremy N Ruskin; Grace Ha; Margaux Forsch; Samer A DeOliveira; Samia Baig; E Kevin Heist; Jason H Wasfy; David F Brown; Paul D Biddinger; Ali S Raja; Benjamin Scirica; Benjamin A White; Moussa Mansour
Journal:  J Am Heart Assoc       Date:  2019-09-12       Impact factor: 5.501

4.  Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries.

Authors:  P P Olimpieri; A Di Lenarda; F Mammarella; L Gozzo; A Cirilli; M Cuomo; M M Gulizia; F Colivicchi; G Murri; D Gabrielli; F Trotta
Journal:  Int J Cardiol Heart Vasc       Date:  2020-01-23

5.  Clinical Management of New-Onset Atrial Fibrillation in COVID-19 Patients Referred to a Tertiary Cardiac Arrhythmia Center after Hospital Discharge.

Authors:  Marco Schiavone; Fabiola B Sozzi; Alessio Gasperetti; Cecilia Gobbi; Elisa Gherbesi; Lucia Barbieri; Roberto Arosio; Gianfranco Mitacchione; Filippo Toriello; Andrea Faggiano; Maurizio Viecca; Giovanni B Forleo; Stefano Carugo
Journal:  J Clin Med       Date:  2022-09-26       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.